Scenario analysis: cost of trastuzumab decreases by 30%.

<p>Scenario analysis: cost of trastuzumab decreases by 30%.</p

One-way sensitivity analysis: tornado plot for pooled subtypes for the age group 50–54 y.

<p>One-way sensitivity analysis: tornado plot for pooled subtypes for the age group 50–54 y.</p

Overall survival.

<p>Curves indicate model outputs. Diamond and triangle markers indicate reported 10-y OS from the N9831 and B-31 trials [<a href="http://www.plosmedicine.org/article/info:doi/10.1371/journal.pmed.1002067#pmed.1002067.ref006" target="_blank">6</a>].</p

Base-case incremental QALYs^DW and costs (2011 New Zealand dollars) per woman treated and ICERs (2011 New Zealand dollars), by age group and subtype.

<p>Base-case incremental QALYs^DW and costs (2011 New Zealand dollars) per woman treated and ICERs (2011 New Zealand dollars), by age group and subtype.</p

Cost-effectiveness acceptability curves.

<p>Cost-effectiveness acceptability curves.</p

Scenario analyses: cost-effectiveness plane for the age group 50–54 y.

<p>GDP, gross domestic product.</p

Health states in the Markov model.

<p>CHF, congestive heart failure.</p

Additional file 2: of BetaMe: impact of a comprehensive digital health programme on HbA1c and weight at 12 months for people with diabetes and pre-diabetes: study protocol for a randomised controlled trial

Health literacy modules. (DOCX 14 kb

Additional file 3: of BetaMe: impact of a comprehensive digital health programme on HbA1c and weight at 12 months for people with diabetes and pre-diabetes: study protocol for a randomised controlled trial

Dissemination policy. (DOCX 18 kb